They have the partnership with us in the back pocket.
And that partnership has shifted into over-drive with the fast track designation, rapidly expanding cohorts and advancing trials. The results are speaking for themselves
I have no doubt Merck is largely responsible for the fast track designation. There’s lots more to come from this partnership and the news will be good and frequent in biotech terms.
Immutep is like a golf ball on a tee, we are all setup. Get in before we get hit.
my opinions only
CHECKPOINT INHIBITORS - What The?, page-19
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
-0.010(3.13%) |
Mkt cap ! $450.9M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 32.8¢ | 31.0¢ | $758.7K | 2.412M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 166349 | 31.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.5¢ | 312504 | 6 |
View Market Depth
| Last trade - 16.10pm 03/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |